PDI seeks new CEO following Marquad retirement

Share this article:
Contract sales firm PDI has announced the retirement of its CEO Michael Marquard.

In a statement issued by the company today, PDI said it will immediately begin a search for a new CEO. While the search is under way, John Dugan, chairman of the board, former CEO and founder of the company, will play a more active role in overseeing operations, PDI said. Jeffrey Smith, PDI's EVP, finance and CFO, has been named interim CEO.

Marquad joined PDI as CEO in May 2006. Prior to joining PDI he was president of Mylan Bertek Pharmaceuticals, VP of Mylan Laboratories and SVP of US sales for Wyeth, where he led a 5,000-person US sales organization. Marquard began his career as a medical sales rep with Lederle Laboratories.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.